Overall patient and treatment characteristics
| . | All patients (N = 64) N (%) . |
|---|---|
| Sex | |
| Male | 38 (59.4) |
| Female | 26 (40.6) |
| Age, median (IQR) | 56 (47-66) |
| Diagnosis | |
| Diffuse large B-cell lymphoma | 49 (76.6) |
| High-grade B-cell lymphoma with MYC and BCL2/BCL6 | 2 (3.1) |
| Primary mediastinal B-cell lymphoma | 4 (6.3) |
| Transformed follicular lymphoma | 2 (3.1) |
| Mantle cell lymphoma | 2 (3.1) |
| Follicular lymphoma | 3 (4.7) |
| B-ALL | 2 (3.1) |
| Number of previous lines of therapy, median (IQR) | 3 (3-4) |
| Previous auto HSCT | 16 (25.0) |
| Time since auto HSCT, days median (IQR) | 602 (276-1108) |
| CAR T-cell product | |
| Axicabtagene ciloleucel | 32 (50.0) |
| Lisocabtagene maraleucel | 1 (1.6) |
| Tisagenlecleucel | 27 (42.2) |
| Other | 2 (3.1) |
| Unknown | 2 (3.1) |
| CAR T-cell therapy conditioning | |
| Fludarabine/cyclophosphamide | 61 (95.3) |
| Bendamustine | 1 (1.6) |
| Other | 1 (1.6) |
| Unknown | 1 (1.6) |
| Time since CAR T-cell infusion, days median (IQR) | 183 (81-461) |
| Variant of SARS-CoV-2 infection | |
| Wild-type | 7 (10.9) |
| Alpha mutation | 3 (4.7) |
| Delta mutation | 4 (6.3) |
| Omicron mutation | 18 (28.1) |
| Unknown | 32 (50.0) |
| ≥1 vaccinations before COVID-19 | 26 (40.6) |
| Comorbidities∗ | |
| Not present | 25 (39.1) |
| 1 comorbidity | 22 (34.4) |
| 2 comorbidities | 10 (15.6) |
| ≥3 comorbidities | 7 (10.9) |
| Leukocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 2515 (1770-3915) |
| Neutrophil count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 1450 (620-2300) |
| Lymphocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 485 (260-899) |
| Severity of infection | |
| At home | 14 (21.9) |
| Admitted to the hospital | 50 (78.1) |
| Duration of hospitalization, days median (IQR) | 20 (7-38) |
| Admitted to the ICU | 18 (28.1) |
| Duration of ICU admittance, days median (IQR) | 11.5 (4.75-30.5) |
| Treatment with MoAbs | 14 (21.9) |
| Treatment with convalescent plasma | 16 (25.0) |
| Treatment with viral replication inhibitor | 18 (28.1) |
| Treatment with steroids | 30 (46.9) |
| Treatment with tocilizumab | 6 (9.4) |
| Outcome | |
| Survived | 38 (59.4) |
| Deceased | 26 (40.6) |
| Attribution of death | |
| COVID-19, or contributed by COVID-19 | 20 (31.2) |
| Hematological malignancy | 6 (9.3) |
| . | All patients (N = 64) N (%) . |
|---|---|
| Sex | |
| Male | 38 (59.4) |
| Female | 26 (40.6) |
| Age, median (IQR) | 56 (47-66) |
| Diagnosis | |
| Diffuse large B-cell lymphoma | 49 (76.6) |
| High-grade B-cell lymphoma with MYC and BCL2/BCL6 | 2 (3.1) |
| Primary mediastinal B-cell lymphoma | 4 (6.3) |
| Transformed follicular lymphoma | 2 (3.1) |
| Mantle cell lymphoma | 2 (3.1) |
| Follicular lymphoma | 3 (4.7) |
| B-ALL | 2 (3.1) |
| Number of previous lines of therapy, median (IQR) | 3 (3-4) |
| Previous auto HSCT | 16 (25.0) |
| Time since auto HSCT, days median (IQR) | 602 (276-1108) |
| CAR T-cell product | |
| Axicabtagene ciloleucel | 32 (50.0) |
| Lisocabtagene maraleucel | 1 (1.6) |
| Tisagenlecleucel | 27 (42.2) |
| Other | 2 (3.1) |
| Unknown | 2 (3.1) |
| CAR T-cell therapy conditioning | |
| Fludarabine/cyclophosphamide | 61 (95.3) |
| Bendamustine | 1 (1.6) |
| Other | 1 (1.6) |
| Unknown | 1 (1.6) |
| Time since CAR T-cell infusion, days median (IQR) | 183 (81-461) |
| Variant of SARS-CoV-2 infection | |
| Wild-type | 7 (10.9) |
| Alpha mutation | 3 (4.7) |
| Delta mutation | 4 (6.3) |
| Omicron mutation | 18 (28.1) |
| Unknown | 32 (50.0) |
| ≥1 vaccinations before COVID-19 | 26 (40.6) |
| Comorbidities∗ | |
| Not present | 25 (39.1) |
| 1 comorbidity | 22 (34.4) |
| 2 comorbidities | 10 (15.6) |
| ≥3 comorbidities | 7 (10.9) |
| Leukocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 2515 (1770-3915) |
| Neutrophil count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 1450 (620-2300) |
| Lymphocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 485 (260-899) |
| Severity of infection | |
| At home | 14 (21.9) |
| Admitted to the hospital | 50 (78.1) |
| Duration of hospitalization, days median (IQR) | 20 (7-38) |
| Admitted to the ICU | 18 (28.1) |
| Duration of ICU admittance, days median (IQR) | 11.5 (4.75-30.5) |
| Treatment with MoAbs | 14 (21.9) |
| Treatment with convalescent plasma | 16 (25.0) |
| Treatment with viral replication inhibitor | 18 (28.1) |
| Treatment with steroids | 30 (46.9) |
| Treatment with tocilizumab | 6 (9.4) |
| Outcome | |
| Survived | 38 (59.4) |
| Deceased | 26 (40.6) |
| Attribution of death | |
| COVID-19, or contributed by COVID-19 | 20 (31.2) |
| Hematological malignancy | 6 (9.3) |
ALL, acute lymphoid leukemia; auto HSCT, autologous HSCT.
One or more comorbidities present (chronic cardiomyopathy, chronic pulmonary disease, diabetes, liver disease, obesity, renal impairment, smoker).